

# Rapid Quantification of an Enkephalin Analgesic in Cerebrospinal Fluid Using the Agilent 1100 Series LC/MSD

# **Application Note**

Steven Rossi and Tony Yaksh, *Department of Anesthesiology University of California, San Diego* 

Wayne Duncan Agilent Technologies

### Introduction

D-penicillamine enkephalin (DPDPE) is a synthetic enkephalin used for control of pain. In the past, this pentapeptide has proven difficult to analyze. Because it has a disulfide bridge, immunoassays have not been predictable. Other methods have required radiolabeling, or have proven to be laborious or lacking in sensitivity. This application note demonstrates the rapid, sensitive analysis of DPDPE in cerebrospinal fluid (CSF), using an Agilent 1100 Series LC/MSD quadrupole mass spectrometer.<sup>1</sup>

### **Experimental**

DPDPE was analyzed in combination with an internal standard (IS) of Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE). Stock solutions were prepared in mobile phase at 1000  $\mu$ g/ml and stored at -70 °C in high-density polyethylene cryovials. These were diluted each day to 1  $\mu$ g/ml in sterile saline and used to spike samples prior to extraction.

Standards of DPDPE were prepared at 1, 5, 10, 100, 500, and 1000 ng/ml in naive CSF. Quality control (QC) samples were prepared in CSF from independent stock solutions.

Study samples were obtained from dogs following spinal injection of 0.3 mg/kg DPDPE. CSF samples were drawn at timed intervals up to 24 hours after administration.

CSF standards, blanks, QC samples, and study samples were all processed using the same procedure. First, 5  $\mu$ l of sample was added to a 0.5-ml high-density polyethylene microcentrifuge tube. Then 5  $\mu$ l of IS solution was added and the mixture was vortexed for five seconds. This solution was loaded onto a conditioned C<sub>18</sub> sample preparation pipette tip (Millipore ZipTip). The ZipTip was then rinsed with five 20- $\mu$ l aliquots of water. The sample was eluted into an autosampler vial with 5  $\mu$ l methanol.



Duplicate 1-µl injections of each sample were analyzed using the Agilent 1100 Series LC/MSD in selected ion monitoring (SIM) mode. Compounds eluting in the first 45 seconds of each analysis were diverted to waste. The guard column was replaced every 100 injections, but the analytical column was rinsed daily with methanol and was used for the duration of the six-month study.

## **Results and Discussion**

Figure 1 shows typical SIM chromatograms from a CSF study sample. The analytes were free of significant interferences throughout the study. The linearity was excellent in the 1-1000 ng/ml range, with the correlation coefficient being 0.9909 and the intercept being 0.0008.




Figure 1. Typical selected ion monitoring chromatograms from study sample

Instrument Conditions				
LC Conditions				
Column:	ZORBAX SB-C <sub>18</sub> , 30 x 2.2 mm, 3.5 μm			
Guard cartridge:	MetaChem Intertsil, 5 x 2 mm, 3 µm			
Flow rate:	0.4 ml/min.			
Injection volume:	1 μl			
Mobile phase:	isocratic 75:25 methanol:10 mmol			
	ammonium formate (pH 3)			
Autosampler temp.:	4 ± 0.5°C			
MS Conditions				
Ionization mode:	positive ESI			
Drying gas flow:	4 I/min			
Nebulizer:	20 psig			
Drying gas temp.:	350°C			
Vcap:	6000 V			
Fragmentor:	80 V			
SIM ions:	646.2 DPDPE			
	570.7 IS			

The limit of quantitation (LOQ) was 1.00 ng/ml. At the LOQ, measured concentrations deviated less than  $\pm$  7.42% from actual, and the precision was 8.1% relative standard deviation (% RSD).

Tables 1 and 2 show the accuracy and precision for the DPDPE analysis. The accuracy was within 10.2% and the precision was within 9.33%.

Table 1.	Accuracy for QC samples of DPDPE (10 replicates on	
6 different days)		

Concentration (ng/ml)		
Nominal	Observed	Accuracy (% deviation)
5	5.10	10.2
100	103.7	3.72
1000	1016.5	1.65

Table 2.	Precision for QC samples of DPDPE (10 replicates on
6 differe	ent days)

	Precision (% RSD)		
Concentration (ng/ml)	Within Day	Between Days	
5	7.16	9.33	
100	4.99	5.39	
1000	0.56	1.51	

Extraction efficiencies were measured between 97% and 102%. A stability study at three concentration levels showed that the extracted samples were stable for 48 hours, with a relative standard deviation of +/-7.4%.

Figure 2 shows the concentration versus time profile for DPDPE in the CSF of dogs administered a single spinal injection of 0.3 mg/kg DPDPE. The pharmacokinetic profile observed in dogs was identical to that of similar hydrophilic opioids in other species.

## Conclusions

This work demonstrates an improved assay for DPDPE in CSF involving extraction using ZipTip pipette tips followed by selected ion monitoring analysis using the Agilent 1100 Series LC/MSD. The assay developed for DPDPE was fast, simple, sensitive, selective, accurate, and precise. Sample recovery and sample stability were excellent. The sample size requirements were very small (5  $\mu$ l), making this an ideal assay for small animals.

#### References

 Steven Rossi and Tony Yaksh. "Rapid Quantification of the δ-Opioid Receptor Selective Enkephalin DPDPE in Canine Cerebrospinal Fluid by Liquid Chromatography – Mass Spectrometry," *Journal of Chromatography*, **772** (2002), 73–79.




Figure 2. Profile of mean DPDPE concentration versus time in cerebrospinal fluid of three dogs, following spinal injection of 0.3 mg/kg DPDPE

#### Authors

*Steven Rossi* and *Tony Yaksh* are scientists at the Department of Anesthesiology, University of California, San Diego. *Wayne Duncan* is a scientist at Agilent Technologies in Palo Alto, California U.S.A.

#### www.agilent.com/chem

Copyright © 2002 Agilent Technologies

Information, descriptions and specifications in this publication are subject to change without notice. Agilent Technologies shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance or use of this material.

All rights reserved. Reproduction, adaptation or translation without prior written permission is prohibited, except as allowed under the copyright laws.

Printed in the U.S.A. September 9, 2002 5988-7750EN

